Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence

Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for HY-1016 extended-release injection, a novel formulation of dienogest for the treatment of endometriosis.

The investigational product represents a Category 2.2 chemical drug filing under China’s regulatory classification system, featuring a novel extended-release formulation and injectable route of administration designed to significantly reduce dosing frequency for patients requiring long-term endometriosis management while maintaining clinical efficacy and safety.

Regulatory Milestone

Disease Background & Current Treatment Landscape

Endometriosis Overview

• Prevalence: Affects approximately 10% of reproductive-age women globally, with an estimated 50 million patients in China
• Pathophysiology: Estrogen-dependent inflammatory condition characterized by endometrial-like tissue growth outside the uterus
• Clinical Burden: Chronic pelvic pain, infertility, dysmenorrhea, and significant impact on quality of life
• Treatment Duration: Requires long-term continuous therapy often spanning years or decades

Current Standard of Care

• First-Line Therapy: Dienogest – highly selective progesterone receptor agonist
• Mechanism: Creates low-estrogen, high-progestogen endocrine environment inducing decidualization of endometrial tissue
• Efficacy: Proven to reduce endometriotic lesions and alleviate symptoms
• Limitations:
• Daily oral dosing requirement leading to adherence challenges
• Gastrointestinal side effects from oral administration
• Peak-trough fluctuations in drug exposure affecting tolerability

HY-1016: Next-Generation Endometriosis Therapy

Product Innovation

• Formulation: Extended-release injectable suspension
• Dosing Frequency: Significantly reduced vs. daily oral administration (specific interval TBD based on clinical data)
• Route of Administration: Subcutaneous or intramuscular injection
• Pharmacokinetic Profile: Sustained therapeutic drug levels with minimized peak-trough fluctuations
• Patient Benefits:
• Improved medication adherence through less frequent dosing
• Enhanced convenience eliminating daily pill burden
• Potentially improved tolerability avoiding first-pass metabolism

Clinical Development Strategy

• Primary Objectives: Demonstrate non-inferiority in efficacy vs. oral dienogest
• Secondary Endpoints: Superior adherence rates, improved quality of life measures, favorable safety profile
• Target Population: Women requiring long-term endometriosis management
• Competitive Differentiation: First-to-market extended-release dienogest formulation in China

Market Opportunity & Commercial Implications

Chinese Endometriosis Market

• Market Size: Estimated USD 800 million–1.2 billion annual market opportunity
• Treatment Gap: Significant unmet need for improved adherence solutions
• Reimbursement Environment: Favorable coverage for innovative women’s health therapeutics
• Patient Demographics: Large addressable population of working-age women seeking convenient treatment options

Competitive Positioning

• First-Mover Advantage: Potential to establish category leadership in extended-release endometriosis therapies
• Premium Pricing: Novel delivery system supports premium reimbursement vs. generic oral dienogest
• Brand Differentiation: Addresses key patient pain points around daily medication burden
• Physician Adoption: Aligns with growing preference for long-acting reversible treatments in chronic conditions

Strategic Value for Huiyu Pharma

• Portfolio Diversification: Expands beyond existing therapeutic areas into high-value women’s health segment
• Innovation Credentials: Demonstrates advanced formulation capabilities in complex drug delivery
• Revenue Potential: Peak annual sales potential of RMB 500 million–800 million (USD 70–110 million) if successful
• Global Licensing Potential: Platform technology could support international partnerships

Development Timeline & Next Steps

Clinical Pathway

• Phase I: Pharmacokinetic and safety studies (initiating Q3 2026)
• Phase II: Dose-finding and preliminary efficacy assessment (expected 2027)
• Phase III: Pivotal efficacy and safety trials vs. standard of care (expected 2028–2029)
• NDA Submission: Targeting 2030 for potential market launch

Regulatory Strategy

• China First: Leveraging domestic regulatory expertise and market knowledge
• International Expansion: Potential global filings following Chinese approval
• Patent Protection: Comprehensive IP strategy covering formulation and manufacturing processes

Investment Considerations

Risk Factors

• Clinical Development Risk: Typical Phase I–III attrition rates apply
• Manufacturing Complexity: Extended-release formulations require specialized production capabilities
• Market Competition: Potential entry of other long-acting endometriosis therapies
• Pricing Pressure: Generic competition in oral dienogest market may impact premium pricing ability

Success Catalysts

• Strong Clinical Data: Demonstrated superiority in adherence and quality of life measures
• Favorable Reimbursement: Inclusion in national insurance formularies
• Physician Education: Effective market development programs highlighting adherence benefits
• Patient Advocacy: Strong support from endometriosis patient organizations

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations. Actual outcomes may differ due to risks including clinical trial results, regulatory decisions, and market dynamics.-Fineline Info & Tech